Buprenorphine in the Treatment of Opioid Dependence

Basic Pharmacology of Opioids

Amass L, Bickel WK, Higgins ST, and Hughes JR. A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification. Journal of Addictive Diseases (13):33–45, 1994.

Cheskin LJ, Fudala PJ, and Johnson RE. A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids. Drug and Alcohol Dependence (36):115–121, 1994.

Chowdhury AN and Chowdhury S. Buprenorphine abuse: Report from India. British Journal of Addictions (85):1,349–1,350, 1990.

Cowan A and Lewis JW (eds.). Buprenorphine: Combating Drug Abuse With a Unique Opioid. New York: Wiley-Liss, 1995.

Doxey JC, Everitt JE, Frank LW, and MacKenzie JE. A comparison of the effects of buprenorphine and morphine on the blood gases of conscious rats. British Journal of Pharmacology (75):118P, 1982.

Eissenberg T, Greenwald MK, Johnson RE, Liebson IA, Bigelow GE, and Stitzer ML. Buprenorphine's physical dependence potential: Antagonist-precipitated withdrawal in humans. Journal of Pharmacology and Experimental Therapeutics (276):449–459, 1996.

Eissenberg T, Johnson RE, Bigelow GE, Walsh SL, Liebson IA, Strain EC, and Stitzer ML. Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients. Drug and Alcohol Dependence (45):81–91, 1997.

Fudala PJ, Yu E, Macfadden W, Boardman C, and Chiang CN. Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts. Drug and Alcohol Dependence (50):1–8, 1998.

Gal TJ. Naloxone reversal of buprenorphine-induced respiratory depression. Clinical Pharmacology and Therapeutics (45):66–71, 1989.

Gray RF, Ferry A, and Jauhar P. Emergence of buprenorphine dependence. British Journal of Addictions (84):1,373–1,374, 1989

Iribarne C, Picart D, Drιano Y, Bail JP, and Berthou F. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sciences (60):1,953–1,964, 1997.

Jasinski DR, Pevnick JS, and Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine. Archives of General Psychiatry (35):501–516, 1978.

Jasinski DR, Fudala PJ, and Johnson RE. Sublingual versus subcutaneous buprenorphine in opiate abusers. Clinical Pharmacology and Therapeutics (45):513–519, 1989.

Johnson RE, Cone EJ, Henningfield JE, and Fudala PJ. Use of buprenorphine in the treatment of opiate addiction. I. Physiologic and behavioral effects during a rapid dose induction. Clinical Pharmacology and Therapeutics (46):335–343, 1989.

Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, and Bigelow GE. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug and Alcohol Dependence (40):17–25, 1995.

Johnson RE, Jaffe JH, and Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. Journal of the American Medical Association (267):2,750–2,755, 1992.

Kobayashi K, Yamamoto T, Chiba K, Tani M, Shimada N, Ishizaki T, and Kuroiwa Y. Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metabolism and Disposition: The Biological Fate of Chemicals (26):818–821, 1998.

Lange WR, Fudala PJ, Dax EM, and Johnson RE. Safety and side effects of buprenorphine in the clinical management of heroin addiction. Drug and Alcohol Dependence (26):19–28, 1990.

Ling W, Wesson D, Charuvastra C, and Klett J. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Archives of General Psychiatry (53):401–407, 1996.

Ling W, Charuvastra C, Collins JF, Batki S, Brown Jr LS, Kintaudi P, Wesson DR, McNicholas L, Tusel DJ, Malkerneker U, Renner Jr JA, Santos E, Casadonte P, Fye C, Stine S, Wang RIH, and Segal D. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial. Addiction(93):475–486, 1998.

Mello NK, Mendelson JH, and Kuehnle JC. Buprenorphine effects on human heroin self-administration: An operant analysis. Journal of Pharmacology and Experimental Therapeutics (223):30–39, 1982.

Mendelson J, Jones RT, Fernandez I, Welm S, Melby AK, and Baggott MJ. Buprenorphine and naloxone interactions in opiate-dependent volunteers. Clinical Pharmacology and Therapeutics (60):105–114, 1996.

Mendelson J, Jones RT, Welm S, Brown J, and Batki SL. Buprenorphine and naloxone interactions in methadone maintenance patients. Biological Psychiatry (41):1,095–1,101, 1997.

Mendelson J, Jones RT, Welm S, Baggott M, Fernandez I, Melby AK, and Nath RP. Buprenorphine and naloxone combinations: The effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers. Psychopharmacology (141):37–46, 1999.

Morrison V. Psychoactive substance use and related behaviors of 135 regular illicit drug users in Scotland. Drug and Alcohol Dependence (23):95–101, 1989.

Nath RP, Upton RA, Everhart ET, Cheung P, Shwonek P, Jones RT, and Mendelson JE. Buprenorphine pharmacokinetics: Relative bioavailability of sublingual tablet and liquid formulations. Journal of Clinical Pharmacology (39):619–623, 1999.

Nigam AK, Ray R, and Tripathi BM. Buprenorphine in opiate withdrawal: A comparison with clonidine. Journal of Substance Abuse Treatment (10):391–394, 1993.

O'Connor JJ, Moloney E, Travers R, and Campbell A. Buprenorphine abuse among opiate addicts. British Journal of Addictions (83):1,085–1,087, 1988.

Parran TV, Adelman CL, Jasinski DR. A buprenorphine stabilization and rapid-taper protocol for the detoxification of opioid-dependent patients. American Journal on Addictions (3):306–313, 1994.

Pickworth WB, Johnson RE, Holicky BA, and Cone EJ. Subjective and physiologic effects of intravenous buprenorphine in humans. Clinical Pharmacology and Therapeutics (53):570–576, 1993.

Preston KL, Bigelow GE, and Liebson IA. Buprenorphine and naloxone alone and in combination in opioid-dependent human volunteers. Psychopharmacology (94):484–490, 1988.

Preston KL, Bigelow GE, and Liebson IA. Effects of sublingually given naloxone in opioid-dependent human volunteers. Drug and Alcohol Dependence (25):27–34, 1990.

Reynaud M, Tracqui A, Petit G, Potard D, and Courty P. Six deaths linked to misuse of buprenorphine-benzodiazepine combination. American Journal of Psychiatry (155):448–449, 1998.

Robinson GM, Dukes PD, Robinson BJ, Cooke RR, and Mahoney GN. The misuse of buprenorphine and a buprenorphine-naloxone combination in Wellington, New Zealand. Drug and Alcohol Dependence (33):81–86, 1993.

Sakol MS, Stark C, and Sykes R. Buprenorphine and temazepam abuse by drug takers in Glasgow: An increase. British Journal of Addiction (84):439–441, 1989.

San L, Camν J, Fernαndez T, Ollι JM, Peri JM, and Torrens M. Assessment and management of opioid withdrawal symptoms in buprenorphine-dependent subjects. British Journal of Addictions (87):55–62, 1992.

Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, and Kosten TR. Buprenorphine versus methadone maintenance for concurrent opioid dependence and cocaine abuse. Archives of General Psychiatry (54):713–720, 1997.

Schuh KJ and Johanson CE. Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet. Drug and Alcohol Dependence (56):55–60, 1999.

Senay EC, Dorus W, Goldberg F, and Thornton W. Withdrawal from methadone maintenance: rate of withdrawal and expectations. Archives of General Psychiatry (34):361–367, 1977.

Singh RA, Mattoo SK, Malhotra A, and Varma VK. Cases of buprenorphine abuse in India. Acta Psychiatrica Scandinavica (86):46–48, 1992.

Strain EC, Preston KL, Liebson IA, and Bigelow GE. Acute effects of buprenorphine, hydromorphone, and naloxone in methadone-maintained volunteers. Journal of Pharmacology and Experimental Therapeutics (261):985–993, 1992.

Strain EC, Preston KL, Liebson IA, and Bigelow GE. Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone. Journal of Pharmacology and Experimental Therapeutics (272):628–638, 1995.

Strain EC, Stitzer ML, Liebson IA, and Bigelow GE. Comparison of buprenorphine versus methadone in the treatment of opioid dependence. American Journal of Psychiatry (151):1,025–1,030, 1994a.

Strain EC, Stitzer ML, Liebson IA, and Bigelow GE. Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users. Psychopharmacology (116):401–406, 1994b.

Strain EC, Stoller K, Walsh SL, and Bigelow GE. Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers. Psychopharmacology (148):374–383, 2000.

Thφrn SE, Rawal N, and Wennhager M. Prolonged respiratory depression caused by sublingual buprenorphine. Lancet January 23, 1985.

Walsh SL, Preston KL, Stitzer ML, Cone EJ, and Bigelow GE. Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clinical Pharmacology and Therapeutics (55):569–580, 1994.

Walsh SL, June HL, Schuh KJ, Preston KL, Bigelow GE, and Stitzer ML. Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacology (119):268–276, 1995.